Literature DB >> 17875050

Autoantibody to alanyl-tRNA synthetase in patients with idiopathic pulmonary fibrosis.

Toru Takahashi1, Ikuo Wada, Yoshinori Ohtsuka, Mitsuru Munakata, Yukihiko Homma, Yoshio Kuroki.   

Abstract

BACKGROUND AND OBJECTIVES: The pathogenesis of IPF is unknown and it is hypothesized that immunological responses are involved. The purpose of this study was to detect autoantibodies in IPF patients and to identify the relevant antigens.
METHODS: Sera from 37 healthy subjects and 22 IPF patients who had no clinical symptoms of collagen vascular disease were examined for immunostaining of A549 human type II cells and human lung tissue. Immunoprecipitation and proteome analysis were performed to identify the antigen.
RESULTS: Fifty per cent of the patient sera and none of the control sera exhibited positive staining. Sera from 10 of the 22 IPF patients showed positive immunohistochemistry and immunoprecipitated a 110-kDa protein from the A549 cell lysate. Sera from only two of 41 patients with collagen vascular disease showed positive immunoreactivity. Proteome analysis using tandem mass spectrometry revealed that the protein was alanyl-tRNA synthetase. Transfection of cDNA of this enzyme into CHO-K1 cells conferred positive staining on these cells with the patients' IgG. The 135-kDa fusion protein consisting of 108-kDa enzyme protein and 27-kDa YFP from the cell lysate of the transfected cells was immunoprecipitated by the patient IgG. In addition, sera from IPF patients significantly inhibited the enzyme activity of alanyl-tRNA synthetase.
CONCLUSION: A significant number of IPF patients possess circulating autoantibodies against alanyl-tRNA synthetase, suggesting the involvement of an autoimmune background in the pathogenesis of IPF.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17875050     DOI: 10.1111/j.1440-1843.2007.01140.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  10 in total

1.  CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis.

Authors:  Syed R Gilani; Louis J Vuga; Kathleen O Lindell; Kevin F Gibson; Jianmin Xue; Naftali Kaminski; Vincent G Valentine; Emily K Lindsay; M Patricia George; Chad Steele; Steven R Duncan
Journal:  PLoS One       Date:  2010-01-29       Impact factor: 3.240

Review 2.  Determinants of initiation and progression of idiopathic pulmonary fibrosis.

Authors:  Robert Matthew Kottmann; Christopher M Hogan; Richard P Phipps; Patricia J Sime
Journal:  Respirology       Date:  2009-09       Impact factor: 6.424

3.  Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.

Authors:  Joyce S Lee; Eunice J Kim; Kara L Lynch; Brett Elicker; Christopher J Ryerson; Tamiko R Katsumoto; Anthony K Shum; Paul J Wolters; Stefania Cerri; Luca Richeldi; Kirk D Jones; Talmadge E King; Harold R Collard
Journal:  Respir Med       Date:  2012-11-24       Impact factor: 3.415

4.  Risk factors for primary Sjögren syndrome-associated interstitial lung disease.

Authors:  Yong Wang; Ziliang Hou; Meihua Qiu; Qiao Ye
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

Review 5.  The utility of comprehensive autoantibody testing to differentiate connective tissue disease associated and idiopathic interstitial lung disease subgroup cases.

Authors:  Caroline V Cotton; Lisa G Spencer; Robert P New; Robert G Cooper
Journal:  Rheumatology (Oxford)       Date:  2017-08-01       Impact factor: 7.580

6.  The HLA class II Allele DRB1*1501 is over-represented in patients with idiopathic pulmonary fibrosis.

Authors:  Jianmin Xue; Bernadette R Gochuico; Ahmad Samer Alawad; Carol A Feghali-Bostwick; Imre Noth; Steven D Nathan; Glenn D Rosen; Ivan O Rosas; Sanja Dacic; Iclal Ocak; Carl R Fuhrman; Karen T Cuenco; Mary A Smith; Susan S Jacobs; Adriana Zeevi; Penelope A Morel; Joseph M Pilewski; Vincent G Valentine; Kevin F Gibson; Naftali Kaminski; Frank C Sciurba; Yingze Zhang; Steven R Duncan
Journal:  PLoS One       Date:  2011-02-23       Impact factor: 3.240

Review 7.  Interrelation Between Fibroblasts and T Cells in Fibrosing Interstitial Lung Diseases.

Authors:  Yunxin Lai; Xinru Wei; Ting Ye; Lilin Hang; Ling Mou; Jin Su
Journal:  Front Immunol       Date:  2021-11-05       Impact factor: 7.561

8.  Association of FcγRIIa R131H polymorphism with idiopathic pulmonary fibrosis severity and progression.

Authors:  Stylianos Bournazos; Jacob Grinfeld; Karen M Alexander; John T Murchison; William A Wallace; Pauline McFarlane; Nikhil Hirani; A John Simpson; Ian Dransfield; Simon P Hart
Journal:  BMC Pulm Med       Date:  2010-10-07       Impact factor: 3.317

9.  Fcγ receptor IIIb (CD16b) polymorphisms are associated with susceptibility to idiopathic pulmonary fibrosis.

Authors:  Stylianos Bournazos; Irini Bournazou; John T Murchison; William A Wallace; Pauline McFarlane; Nikhil Hirani; A John Simpson; Ian Dransfield; Simon P Hart
Journal:  Lung       Date:  2010-10-06       Impact factor: 2.584

Review 10.  Interpretation of autoantibody positivity in interstitial lung disease and lung-dominant connective tissue disease.

Authors:  Daniel Antunes Silva Pereira; Alexandre de Melo Kawassaki; Bruno Guedes Baldi
Journal:  J Bras Pneumol       Date:  2013 Nov-Dec       Impact factor: 2.624

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.